



August 3, 2022

Name of Company: Meiji Holdings Co., Ltd.

Name of Representative: Kazuo Kawamura, CEO, President and Representative Director

Code Number: 2269, Prime Market, Tokyo Stock Exchange

Notice concerning Additional Approval in Japan for Freeze-dried, Cell Culture-Derived
Smallpox Vaccine LC16 “KMB” for Prevention of Monkeypox

Meiji Holdings Co., Ltd. announces that its subsidiary, KM Biologics has received approval from the Ministry of Health, Labour and Welfare (MHLW) for its Freeze-dried, Cell Culture-Derived Smallpox Vaccine LC16 “KMB” for an additional indication of prevention of monkeypox on August 2, 2022.

This additional approval will not have a material impact on the consolidated financial results for the fiscal year ending March 31, 2023.

#####